D

Dizal Jiangsu Pharmaceutical Co Ltd
SSE:688192

Watchlist Manager
Dizal Jiangsu Pharmaceutical Co Ltd
SSE:688192
Watchlist
Price: 45.1 CNY -3.34% Market Closed
Market Cap: 18.7B CNY
Have any thoughts about
Dizal Jiangsu Pharmaceutical Co Ltd?
Write Note

Dizal Jiangsu Pharmaceutical Co Ltd
Total Receivables

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Dizal Jiangsu Pharmaceutical Co Ltd
Total Receivables Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Receivables CAGR 3Y CAGR 5Y CAGR 10Y
D
Dizal Jiangsu Pharmaceutical Co Ltd
SSE:688192
Total Receivables
ÂĄ85.5m
CAGR 3-Years
125%
CAGR 5-Years
31%
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Total Receivables
ÂĄ3.2B
CAGR 3-Years
77%
CAGR 5-Years
49%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Total Receivables
ÂĄ3.1B
CAGR 3-Years
62%
CAGR 5-Years
72%
CAGR 10-Years
N/A
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
Total Receivables
ÂĄ1.1B
CAGR 3-Years
15%
CAGR 5-Years
0%
CAGR 10-Years
24%
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Total Receivables
ÂĄ25.5B
CAGR 3-Years
43%
CAGR 5-Years
44%
CAGR 10-Years
48%
Imeik Technology Development Co Ltd
SZSE:300896
Total Receivables
ÂĄ230.8m
CAGR 3-Years
72%
CAGR 5-Years
75%
CAGR 10-Years
N/A
No Stocks Found

Dizal Jiangsu Pharmaceutical Co Ltd
Glance View

Market Cap
18.4B CNY
Industry
Biotechnology

Dizal (Jiangsu) Pharmaceutical Co., Ltd. engages in the discovery, development, and commercialization of innovative medicines. The company is headquartered in Shanghai, Shanghai and currently employs 328 full-time employees. The company went IPO on 2021-12-10. The firm focuses on diseases such as malignant tumors and immune diseases. The main candidate innovative drugs in the Company's research and development (R&D) pipeline are DZD4205, DZD9008, DZD1516, DZD2269, DZD8586, DZD0095. The firm is still in the R&D stage.

Intrinsic Value
30.31 CNY
Overvaluation 33%
Intrinsic Value
Price
D

See Also

What is Dizal Jiangsu Pharmaceutical Co Ltd's Total Receivables?
Total Receivables
85.5m CNY

Based on the financial report for Dec 31, 2023, Dizal Jiangsu Pharmaceutical Co Ltd's Total Receivables amounts to 85.5m CNY.

What is Dizal Jiangsu Pharmaceutical Co Ltd's Total Receivables growth rate?
Total Receivables CAGR 5Y
31%

Over the last year, the Total Receivables growth was 821%. The average annual Total Receivables growth rates for Dizal Jiangsu Pharmaceutical Co Ltd have been 125% over the past three years , 31% over the past five years .

Back to Top